Shots:
- The UK’s MHRA has approved Gobivaz (50mg/0.5mL & 100mg/mL in PFS & autoinjector), a biosimilar version of Simponi (golimumab) for the treatment of rheumatoid arthritis, PsA, axial spondylarthritis & ulcerative colitis in adult pts & juvenile idiopathic arthritis, following CHMP’s positive opinion
- Additionally, Alvotech is responsible for the development & commercial supply of Gobivaz, while Advanz Pharma handles registration & holds exclusive commercialization rights in the EU & the UK
- Golimumab is an IgG1 monoclonal antibody that targets TNF-alpha, resulting in the decrease of inflammatory markers like CRP, IL-6, ICAM-1, MMP-3, & VEGF for treating chronic inflammatory & immune-mediated diseases
Ref: GlobeNewswire| Image: Alvotech & Advanz Pharma | Press Release
Related News:- Alvotech and Advanz Pharma Report the EMA’s MAA Acceptance of AVT23 (Biosimilar, Xolair)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
